Dermatitis, Atopic: Clinical Trials

9 terminated. 9 Phase 3, 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	9	Terminated 9
Phase 2	2	Terminated 2

Follow Dermatitis, Atopic: new trials by email Literature Review of Dermatitis, Atopic trials Research Report on Dermatitis, Atopic

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Rocatinlimab, Placebo - Atopic Dermatitis	Phase 3	Terminated	Amgen	2621	2023-05-31	2026-07-16
A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection etrasimod, Placebo - Atopic Dermatitis, Atopic Dermatitis, Unspecified	Phase 2 / Phase 3	Terminated	Pfizer	58	2023-01-18	2025-05-08
Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis difelikefalin 0.25 mg, difelikefalin 0.5 mg, TCS Cream - Pruritus, Atopic Dermatitis	Phase 3	Terminated	Cara Therapeutics, Inc.	287	2022-08-16	2024-02-22
Effects of Tralokinumab in the Skin: an Immunologic and Molecular Investigation Application of Tralokinumab - Atopic Dermatitis	Phase 2 / Phase 3	Terminated	University of Zurich	24	2022-06-15	2026-02-06
A Study of the Long-Term Safety of Crisaborole Ointment, 2% in Japanese Pediatric and Adult Participants With Mild to Moderate Atopic Dermatitis Crisaborole 2% - Atopic Dermatitis	Phase 3	Terminated	Pfizer	40	2020-09-14	2021-08-12
Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2) Tradipitant, Placebo - Atopic Dermatitis	Phase 3	Terminated	Vanda Pharmaceuticals	87	2019-10-21	2024-05-14
A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis Baricitinib - Atopic Dermatitis	Phase 3	Terminated	Eli Lilly and Company	374	2018-06-27	2022-11-08
Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch) 5 mg Serlopitant Tablets - Pruritus, Prurigo Nodularis	Phase 3	Terminated	Vyne Therapeutics Inc.	558	2018-03-15	2021-05-20
Efficacy Study of Topical Twice Weekly Fluticasone Treatment to Reduce Relapse in Atopic Dermatitis in Children Fluticasone, cream, Placebo, - Dermatitis, Atopic	Phase 3	Terminated	Elena Rubio Gomis	54	2009-12-01	2015-01-09

Narrower conditions

Eczema (6)  ·  Pruritus (2)  ·  Psoriasis (1)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (9)  ·  Dermatitis (9)  ·  Genetic Diseases, Inborn (9)  ·  Hypersensitivity (9)  ·  Hypersensitivity, Immediate (9)  ·  Immune System Diseases (9)  ·  Skin Diseases (9)  ·  Skin Diseases, Eczematous (9)  ·  Skin Diseases, Genetic (9)  ·  Skin and Connective Tissue Diseases (9)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Signs and Symptoms (2)  ·  Skin Manifestations (2)  ·  Skin Diseases, Papulosquamous (1)

Interventions

Fluticasone (1)  ·  KHK4083 (1)  ·  baricitinib (1)  ·  difelikefalin (1)  ·  etrasimod (1)  ·  serlopitant (1)

Sponsors

Pfizer (2)  ·  Amgen (1)  ·  Cara Therapeutics, Inc. (1)  ·  Elena Rubio Gomis (1)  ·  Eli Lilly and Company (1)  ·  University of Zurich (1)  ·  Vanda Pharmaceuticals (1)  ·  Vyne Therapeutics Inc. (1)

Countries

United States (6)  ·  Canada (3)  ·  Poland (3)  ·  Austria (2)  ·  Czechia (2)  ·  Germany (2)  ·  Japan (2)  ·  Puerto Rico (2)  ·  Spain (2)  ·  Switzerland (2)  ·  Argentina (1)  ·  Australia (1)  ·  Belgium (1)  ·  Brazil (1)  ·  Bulgaria (1)

Top investigators

Elena Rubio Gomis, PhD MD (1)  ·  Peter Schmid-Grendelmeier, Prof, MD (1)

Results publications

PMID 33826132, PMID 36749121

NIH funding

2008 (1), 2017 (1)